Compare AU

Compare DRUG vs. AEBD

Compare shares and ETFs on the ASX that you can trade on Pearler.

BetaShares Global Healthcare Currency Hedged ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare Currency Hedged ETF (DRUG) and the BetaShares Ethical Australian Composite Bond ETF (AEBD). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

DRUG

AEBD

Popularity

Low

Low

Pearlers invested

61

1

Median incremental investment

$920.50

$5,000.00

Median investment frequency

Monthly

Monthly

Median total investment

$1,892.10

$5,006.43

Average age group

26 - 35

> 35


Key Summary

DRUG

AEBD

Strategy

DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars.

AEBD.AX was created on 2024-11-04 by BetaShares. The fund's investment portfolio concentrates primarily on broad credit fixed income. The investment objective of the Fund is to provide an investment return that aims to track the performance of the Bloomberg Australian Enhanced Yield Ethically Screened Composite Bond Index, before taking into account fees and expenses.

Top 3 holdings

CHF - SWISS FRANC (0 %)

AUD - AUSTRALIA DOLLAR (0 %)

DKK - DANISH KRONE (0 %)

MANITOBA (PROVINCE OF) 4.85% AUG-34 (3.65 %)

EUROPEAN INVESTMENT BANK 1.9% FEB-36 (3.44 %)

INTER-AMERICAN DEVEL BK 1.0% AUG-28 (3.31 %)

Top 3 industries

Other (75.53 %)

Communication Services (33.53 %)

Health Care (24.47 %)

Top 3 countries

United States (71.71 %)

Switzerland (8.14 %)

Denmark (6.30 %)

Management fee

0.57 %

0 %


Key Summary

DRUG

AEBD

Issuer

BetaShares

BetaShares

Tracking index

Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD

Bloomberg Australian Enhanced Yield Composite Bond Index - Benchmark TR Gross

Asset class

ETF

ETF

Management fee

0.57 %

0 %

Price

$7.95

$50.57

Size

$185.172 million

N/A

10Y return

N/A

N/A

Annual distribution yield (5Y)

1.90 %

0.05 %

Market

ASX

ASX

First listed date

08/08/2016

05/11/2024

Purchase fee

$6.50

$6.50


Community Stats

DRUG

AEBD

Popularity

Low

Low

Pearlers invested

61

1

Median incremental investment

$920.50

$5,000.00

Median investment frequency

Monthly

Monthly

Median total investment

$1,892.10

$5,006.43

Average age group

26 - 35

> 35


Pros and Cons

DRUG

AEBD

Pros

  • Higher exposure to US market

  • Higher price growth

  • Higher distribution yield

  • Lower management fee

Cons

  • Higher management fee

  • Lower exposure to US market

  • Lower price growth

  • Lower distribution yield

DRUG

AEBD

Higher exposure to US market

Lower exposure to US market

Higher management fee

Lower management fee

Higher price growth

Lower price growth

Higher distribution yield

Lower distribution yield

Home